Could your sleep habits influence cancer treatment success?
NCT ID NCT07662005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether sleep patterns—like duration, quality, and heart rate during sleep—are linked to how well stomach cancer responds to immunotherapy before surgery. Researchers will monitor sleep non-invasively in 120 patients with locally advanced gastric or gastroesophageal junction cancer. The goal is to see if better sleep is associated with a stronger tumor shrinkage after treatment. No changes are made to standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If sleep patterns are linked to treatment response, this could help personalize cancer care by identifying patients who might benefit from sleep interventions.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may not lead to changes in treatment or outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with histologically confirmed locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who are assessed as resectable by imaging or a multidisciplinary team and are scheduled to receive neoadjuvant immunotherapy followed by radical surgery. Eligible participants should have stage II-III disease without distant metastasis, an ECOG performance status of 0-1, and no prior systemic anticancer therapy for the current tumor at study baseline.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age greater than 18 years, regardless of sex. 2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. 3. Locally advanced, resectable disease as assessed by imaging or a multidisciplinary team, based on the 8th edition of the AJCC staging system, typically cT3-4a, any N, or any T with N-positive disease, corresponding to stage II-III disease, without distant metastasis. 4. Scheduled to receive neoadjuvant therapy followed by radical surgery. 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. 6. No prior systemic anticancer therapy for the current tumor at study baseline. 7. Willing to participate in the study and able to provide written informed consent. Exclusion Criteria: 1. Presence of distant metastasis, peritoneal metastasis, or disease considered no longer suitable for curative-intent treatment. 2. Prior neoadjuvant chemotherapy, immunotherapy, radiotherapy, or other systemic anticancer therapy for the current tumor. 3. Severe cognitive impairment, acute psychiatric disorder, or any other condition that prevents the participant from completing study procedures. 4. Current treatment with antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications, with any of the following occurring within 4 weeks before enrollment: 1. Increase or decrease in the dose of the relevant medication by 25% or more from the previous maintenance dose; 2. Initiation, discontinuation, or replacement of antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications; 3. Adjustment of treatment due to worsening anxiety, depression, insomnia, or other psychiatric or psychological symptoms; 4. Any medication change or psychological condition judged by the investigator to potentially affect sleep monitoring results or study compliance. 5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily pill slow the visible signs of aging?
- One small incision vs several: robotic stomach cancer surgery put to the test
- Can PET scans reveal which stomach cancers will respond to immunotherapy?
- Does soreness after exercise disrupt sleep more for people with insomnia?
- Can teaching parents about sleep help kids with developmental conditions?
- Can a bed that changes temperature deepen your sleep?